- Botensilimab (also known as AGEN1181) is a novel, next-generation, Fc-enhanced, immunoglobulin G1 (IgG1) antibody1234. It is a multifunctional CTLA-4 investigational antibody that has been designed to extend clinical benefits to “cold” tumors that have not historically responded to standard of care or investigational therapies4. The antibody was designed to enhance FcγR effector functions while avoiding complement-related toxicities and has demonstrated activity in cancer patients for whom current immuno-oncology agents have historically been ineffective1.Learn more:✕This summary was generated using AI based on multiple online sources. To view the original source information, use the "Learn more" links.Botensilimab is a novel innate and adaptive immune activator that binds CTLA-4. The antibody was designed to enhance FcγR effector functions while avoiding complement-related toxicities and has demonstrated activity in cancer patients for whom current immuno-oncology agents have historically been ineffective.www.globenewswire.com/news-release/2022/09/12…Botensilimab (also known as AGEN1181) is a next-generation, Fc-enhanced, immunoglobulin G1 (IgG1) antibody which has shown significant activity in activating both the innate and adaptive immune response.www.biospace.com/article/releases/agenus-annou…Agenus’ next-generation CTLA-4 antibody Botensilimab was designed to: Extend the curative benefits of I-O to cold tumors that do not respond to approved immunotherapies. This is achieved by optimizing T cell interactions to drive increased potency.agenusbio.com/Botensilimab is a novel, multifunctional CTLA-4 investigational antibody that has been designed to extend clinical benefits to “cold” tumors that have not historically responded to standard of care or investigational therapies.investor.agenusbio.com/news/news-details/2023/A…
- People also ask
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC …
WEB3 hours ago · Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line …
Agenus Inc. - Agenus Completes Enrollment in Randomized Phase …
WEBOct 10, 2023 · Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line …
Agenus Inc. - Botensilimab/Balstilimab Breakthrough Data …
WEBJanuary 22, 2024. Download. Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor …
WEBBOTENSILIMAB PROMOTES RESPONSES IN SUBTYPES UNRESPONSIVE TO I-O (N=13) + = Ongoing response. Best Percent Change in Target Lesions (%) 13 + + + + …
Agenus Inc. - FDA Grants Agenus Type B End-of-Phase 2 Meeting …
WEBMay 16, 2024 · Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will …
Results from a phase 1a/1b study of botensilimab (BOT), a novel …
WEBJan 24, 2023 · Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in …
WEB40% I-O ELIGIBLE. FIRST I-O REVOLUTION: PD-(L)1 ± CTLA-4. Paradigm shift: curative potential. Majority do not benefit from I-O treatment. 0% LAST DECADE. 2022. Agenus …
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination …
WEBOct 21, 2023 · LEXINGTON, Mass.-- ( BUSINESS WIRE )--Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today …
Agenus Receives Fast Track Designation for Botensilimab and …
WEBApr 17, 2023 · LEXINGTON, Mass.-- ( BUSINESS WIRE )--Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer …
Agenus Shows Unprecedented Activity for - GlobeNewswire
WEBLEXINGTON, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to …
Skip to content
